After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Akero Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Akero Therapeutics Inc is $4.02B. A total of 1.06 million shares were traded on the day, compared to an average of 1.57M shares.
In the most recent transaction, Rolph Timothy sold 12,500 shares of AKRO for 49.30 per share on Aug 05 ’25. After the transaction, the Chief Scientific Officer now owns 167,124 company shares. In a previous transaction on Jul 16 ’25, Yale Catriona sold 10,000 shares at 52.95 per share. AKRO shares that Chief Development Officer owns now total 91,488.
Among the insiders who sold shares, Cheng Andrew disposed of 30,000 shares on Jul 10 ’25 at a per-share price of $51.16. This resulted in the President and CEO holding 520,757 shares of AKRO after the transaction. In another insider transaction, Rolph Timothy sold 12,500 shares at $51.09 per share on Jul 07 ’25. Company shares held by the Chief Scientific Officer now total 167,124.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, AKRO has a high of $58.40 and a low of $21.34.
As of this writing, AKRO has an earnings estimate of $-0.94 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of $-0.91 per share and a lower estimate of $-1.0. The company reported an EPS of $-1.05 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $12.84, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock.
